Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Blood (2023) 142 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2023-182946

Published: 2023

Journal Articles

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

Blood (2022) 140 (12): 1378–1389.

https://doi.org/10.1182/blood.2021014270

Published: 2022

Includes: Supplemental data

Journal Articles

A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Blood (2021) 138 (Supplement 1): 41.

https://doi.org/10.1182/blood-2021-146773

Published: 2021

Journal Articles

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Alessandro Pulsoni, MD, Maria Elena Tosti, Statistician, Simone Ferrero, MD, Stefano Luminari, MD, Anna Marina Liberati, Natalia Cenfra, MD, Daniela Renzi, MD, Emanuela Zanni, MD, Carola Boccomini, MD, Andres JM Ferreri, MD, Sara Rattotti, Vittorio Ruggero Zilioli, MD, Patrizia Bernuzzi, MD, Silvia Bolis, MD, Gerardo Musuraca, MD, Luca Nassi, Tommasina Perrone, MD, Caterina Stelitano, MD, Antonella Anastasia, MD, Paolo Corradini, MD, Giovanni Partesotti, MD, Francesca Re, Emanuele Cencini, MD, Clara Mannarella, MD, Donato Mannina, MD, Anna Lia Molinari, MD, Monica Tani, MD, Giorgia Annechini, MD, Giovanni Manfredi Assanto, MD, Lavinia Grapulin, MD, Irene Della Starza, PhD, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Elena Ciabatti, Barbara Mantoan, PhD, Anna Guarini, PhD, Luca Arcaini, Umberto Ricardi, MD, Valter Gattei, MD, Sara Galimberti, MD PhD, Marco Ladetto, MD, Ilaria Del Giudice, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 124.

https://doi.org/10.1182/blood-2019-123106

Published: 2019

Journal Articles

Targeted Locus Amplification (TLA): A Novel Next Generation Sequencing (NGS) Technology to Detect New Molecular Markers and Monitoring Minimal Residual Disease (MRD) in Mantle Cell and Follicular Lymphoma

Blood (2017) 130 (Supplement 1): 2742.

https://doi.org/10.1182/blood.V130.Suppl_1.2742.2742

Published: 2017

Journal Articles

Standardized IGH-Based Next-Generation Sequencing for MRD Detection in Follicular Lymphoma

Christiane Pott, MD, PhD, Henrik Knecht, PhD, Arved Herzog, Elisa Genuardi, Michael Unterhalt, MD PhD, Barbara Mantoan, Irene Dogliotti, Wolfgang Hiddemann, MD PhD, Mario Boccadoro, Dietrich Herrmann, Michael Kneba, MD, Anton W Langerak, Nikos Darzentas, Patricia Groenen, Monika Brüggemann, MD, Eva Hoster, Marco Ladetto, Simone Ferrero

Blood (2017) 130 (Supplement 1): 1491.

https://doi.org/10.1182/blood.V130.Suppl_1.1491.1491

Published: 2017

Journal Articles

Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy

Stefania Oliva, MD, Manuela Gambella, Alessandra Larocca, Stefano Spada, Eleonora Marzanati, Barbara Mantoan, Sara Grammatico, Concetta Conticello, MD, Barbara Gamberi, Massimo Offidani, Anna Marina Liberati, Chiara Pautasso, Paola Omedé, Antonio Palumbo, MD, Mario Boccadoro

Blood (2016) 128 (22): 4409.

https://doi.org/10.1182/blood.V128.22.4409.4409

Published: 2016

Journal Articles

Highly Sensitive Droplet Digital PCR for MYD88 L265P Mutation Detection and Minimal Residual Disease Monitoring in Waldenström Macroglobulinemia

Daniela Drandi, Elisa Genuardi, Paola Ghione, Daniele Grimaldi, Barbara Mantoan, Marina Ruggeri, Daniela Barbero, Luigia Monitillo, Marika Vasta, Eleonora Marzanati, Giulia Verardo, Paola Omedè, Federica Cavallo, Mario Boccadoro, MD, Marco Ladetto, Simone Ferrero

Blood (2015) 126 (23): 2645.

https://doi.org/10.1182/blood.V126.23.2645.2645

Published: 2015

Journal Articles

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Blood (2013) 122 (23): 3759–3766.

https://doi.org/10.1182/blood-2013-06-507319

Published: 2013

Includes: Supplemental data

Journal Articles

Improved Igh-Based MRD Detection By Using Droplet Digital PCR: a Comparison With Real Time Quantitative PCR In MCL and MM

Blood (2013) 122 (21): 4290.

https://doi.org/10.1182/blood.V122.21.4290.4290

Published: 2013

Journal Articles

A Comparative Analysis Of Next-Generation Sequencing and Real-Time Quantitative PCR For Minimal Residual Disease Detection In Follicular Lymphomas

Christiane Pott, M.D. Ph.D., Luigia Monitillo, Elisa Genuardi, Barbara Mantoan, Heiko Trautmann, PhD, Michael Kneba, MD, Monika Brüggemann, MD, Malek Faham, MD, PhD, Marco Ladetto

Blood (2013) 122 (21): 4293.

https://doi.org/10.1182/blood.V122.21.4293.4293

Published: 2013

Journal Articles

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

Blood (2013) 122 (21): 551.

https://doi.org/10.1182/blood.V122.21.551.551

Published: 2013

Journal Articles

Minimal Residual Disease Evaluated As Bcl2/Igh Rearrangement After Conventional Treatment Does Significantly Impact On Progression-Free Survival of Patients Affected by Follicular Lymphoma: The Experience of the Ancillary Trial Conducted by the Fondazione Italiana Linfomi (FIL)

Blood (2012) 120 (21): 3653.

https://doi.org/10.1182/blood.V120.21.3653.3653

Published: 2012

Journal Articles

PCR-Based Minimal Residual Disease (MRD) Detection Is a Strong Independent Outcome Predictor Also in Rituximab-Intensive Non-ASCT-Based Programs: Results From the ML17638 Multicenter Randomised Phase III Trial for Elderly Follicular Lymphoma (FL) Patients of the Fondazione Italiana Linfomi (FIL)

Blood (2012) 120 (21): 787.

https://doi.org/10.1182/blood.V120.21.787.787

Published: 2012

Journal Articles

Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL)

Blood (2011) 118 (21): 777.

https://doi.org/10.1182/blood.V118.21.777.777

Published: 2011

Journal Articles

Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcome

Blood (2011) 118 (21): 2845.

https://doi.org/10.1182/blood.V118.21.2845.2845

Published: 2011

Journal Articles

Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.

Blood (2009) 114 (22): 1706.

https://doi.org/10.1182/blood.V114.22.1706.1706

Published: 2009

Journal Articles

Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases.

Blood (2009) 114 (22): 2808.

https://doi.org/10.1182/blood.V114.22.2808.2808

Published: 2009

Journal Articles

Persistent Telomeric Loss and Functional Impairment of Ph-Negative Hematopoiesis after Successful Treatment of Chronic Myelogenous Leukemia

Blood (2008) 112 (11): 3183.

https://doi.org/10.1182/blood.V112.11.3183.3183

Published: 2008

Journal Articles

Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial

Blood (2008) 112 (11): 834.

https://doi.org/10.1182/blood.V112.11.834.834

Published: 2008

NARROW

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Targeted Locus Amplification (TLA): A Novel Next Generation Sequencing (NGS) Technology to Detect New Molecular Markers and Monitoring Minimal Residual Disease (MRD) in Mantle Cell and Follicular Lymphoma

Standardized IGH-Based Next-Generation Sequencing for MRD Detection in Follicular Lymphoma

Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy

Highly Sensitive Droplet Digital PCR for MYD88 L265P Mutation Detection and Minimal Residual Disease Monitoring in Waldenström Macroglobulinemia

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Improved Igh-Based MRD Detection By Using Droplet Digital PCR: a Comparison With Real Time Quantitative PCR In MCL and MM

A Comparative Analysis Of Next-Generation Sequencing and Real-Time Quantitative PCR For Minimal Residual Disease Detection In Follicular Lymphomas

Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial

Minimal Residual Disease Evaluated As Bcl2/Igh Rearrangement After Conventional Treatment Does Significantly Impact On Progression-Free Survival of Patients Affected by Follicular Lymphoma: The Experience of the Ancillary Trial Conducted by the Fondazione Italiana Linfomi (FIL)

PCR-Based Minimal Residual Disease (MRD) Detection Is a Strong Independent Outcome Predictor Also in Rituximab-Intensive Non-ASCT-Based Programs: Results From the ML17638 Multicenter Randomised Phase III Trial for Elderly Follicular Lymphoma (FL) Patients of the Fondazione Italiana Linfomi (FIL)

Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (FIL)

Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcome

Rituximab (R) Maintenance Versus Observation After Short Term Chemoimmunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.

Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases.

Persistent Telomeric Loss and Functional Impairment of Ph-Negative Hematopoiesis after Successful Treatment of Chronic Myelogenous Leukemia

Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only